Please provide your email address to receive an email when new articles are posted on . CHICAGO — Family physicians are effective in their classifications of diabetic retinopathy using a telemedicine ...

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today ...

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...

Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now (Reuters) — Google said on Thursday it had ...

A multicenter randomized controlled trial was conducted to assess the impact of a web-based, diabetes evaluation portal and team-based care on outcomes in patients with diabetic kidney disease. A ...

With real-time monitoring, school nurses can now track a student’s blood sugar levels throughout the day without waiting for ...

The MarketWatch News Department was not involved in the creation of this content. SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or ...

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentum DIAMOND program committees expanded with globally renowned retina experts If ...

ROCKVILLE, Md., Aug. 7, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ...

LOS ANGELES, CA, UNITED STATES, September 12, 2024 /EINPresswire.com/ -- Anywhere Foot and Ankle Care, a leader in mobile podiatric services, is excited to announce ...

--Ocular Therapeutix, Inc., an integrated biopharmaceutical company committed to redefining the retina experience, will host an Investor Day today where it will highlight outstanding progress in the ...